- Topline-Zwischendatensatz von GALAXIES Lung-201 mit >240 Patienten für das 2. Quartal 2025 erwartet - Zwischendatensätze von GALAXIES H&N-202 und TIG-006 HNSCC mit ~200 Patienten für 2025 erwartet- Abgeschlossene Rekrutierung der zweiten Dosis-Kohorte der EOS-984 + Pembrolizumab-Kombination in der laufenden Phase-1-Studie- Beginn der Patientenrekrutierung in der Phase-I-Studie TRM-010 mit EOS-215 für das 2. Quartal 2025…
Tue, 03 Jun 2025 04:18:00 GMT More bad news in biotech: Watertown cancer firm iTeos shutting down. The offices of GlaxoSmithKline in London. Luke MacGregor/Bloomberg ... according to a May 28 company news release.
Wed, 28 May 2025 05:30:00 GMT WATERTOWN, Mass. and GOSSELIES, Belgium, May 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...
Tue, 13 May 2025 05:55:00 GMT WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...
Tue, 13 May 2025 05:55:00 GMT WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...
Tue, 13 May 2025 05:55:00 GMT WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...
